The Mosaic Bioprosthesis in the Aortic Position: 17 Years' Results

Abstract

Background The Mosaic bioprosthesis (Medtronic Inc., Minneapolis, Minnesota, United States), a stented porcine aortic valve, combines glutaraldehyde fixation with zero-pressure, root-pressure techniques and antimineralization treatment with amino-oleic acid for improved hemodynamics and tissue durability. The first device has been implanted worldwide at the authors' institution in September 1993. The aim of the present study was to collect mid- to long-term data of the prosthesis.

Materials and Methods A total of 272 patients (124 males and 148 females) underwent isolated aortic valve replacement with the Mosaic bioprosthesis between September 1993 and August 2007. Median age at implant was 76.8 years (range, 31.3 to 90.7). Median follow-up was 12.0 years (range, 0 to 17.2 years); follow-up was complete for 223 (82%) patients.

Results Early mortality (30 days) was 4% (12 patients). Overall survival at 5, 10, 15, and 17 years was 68.6% ± 3.1%, 36.4% ± 3.3%, 17.1% ± 3.6%, and 10.7% ± 4.3%, respectively. Eleven late deaths (5%) were cardiac related. There were 24 thromboembolic events, 1 hemorrhagic, and 6 reoperations/explants. At a median follow-up of 12 years, freedom from any cause of death was 27.0% ± 3.2% acting as a competing risk for the incidence of thromboembolic events (16.4% ± 3.5%), hemorrhage (0.5% ± 0.5%), and reoperation/explant (4.1% ± 1.8%). Two redos were due to structural valve deterioration (SVD), two for nonstructural dysfunction (paravalvular leakage), one for thrombosed prosthesis, and one for endocarditis.

Conclusions Performance and late outcome of the Mosaic bioprosthesis was satisfactory during 17 years after clinical introduction. The Mosaic bioprosthesis showed low incidence of SVD or need for reoperation in the long term.

Keywords

bioprosthesis - aortic valve replacement

Note

Presented at the 41st annual meeting of the German Society for Thoracic and Cardiovascular Surgery, Freiburg, Germany, February 12 to 15, 2012.

• References

• 1 Eichinger WB, Botzenhardt F, Günzinger R , et al. European experience with the Mosaic bioprosthesis. J Thorac Cardiovasc Surg 2002; 124 (2) 333-339
• 2 Celiento M, Ravenni G, Milano AD , et al. Aortic valve replacement with the Medtronic Mosaic bioprosthesis: a 13-year follow-up. Ann Thorac Surg 2012; 93 (2) 510-515
• 3 Eichinger WB, Günzinger R, Botzenhardt F, Simmerl D, Gansera B, Kemkes BM. The Mosaic bioprosthesis in the aortic position at five years. J Heart Valve Dis 2000; 9 (5) 653-660
• 4 Gansera B, Botzenhardt F, Günzinger R, Spiliopoulos K, Angelis I, Kemkes BM. The Mosaic bioprosthesis in the aortic position: seven years' results. J Heart Valve Dis 2003; 12 (3) 354-361
• 5 Edmunds Jr LH, Clark RE, Cohn LH, Grunkemeier GL, Miller DC, Weisel RD. Guidelines for reporting morbidity and mortality after cardiac valvular operations. The American Association for Thoracic Surgery, Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity. Ann Thorac Surg 1996; 62 (3) 932-935
• 6 Johnson DM, Sapirstein W. FDA's requirements for in-vivo performance data for prosthetic heart valves. J Heart Valve Dis 1994; 3 (4) 350-355
• 7 Grunkemeier GL, Jin R, Eijkemans MJ, Takkenberg JJM. Actual and actuarial probabilities of competing risks: apples and lemons. Ann Thorac Surg 2007; 83 (5) 1586-1592
• 8 Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 2008; 26 (24) 4027-4034
• 9 Gray B. Cmprsk: Subdistribution Analysis of Competing Risks. 2011; R package version 2.2–2. Available at: http://CRAN.R-project.org/package=cmprsk
• 10 Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154
• 11 Bonow RO, Carabello BA, Kanu C , et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006; 114 (5) e84-e231
• 12 Jamieson WR, Janusz MT, MacNab J, Henderson C. Hemodynamic comparison of second- and third-generation stented bioprostheses in aortic valve replacement. Ann Thorac Surg 2001; 71 (5, Suppl): S282-S284
• 13 Eichinger WB, Botzenhardt F, Keithahn A , et al. Exercise hemodynamics of bovine versus porcine bioprostheses: a prospective randomized comparison of the mosaic and Perimount aortic valves. J Thorac Cardiovasc Surg 2005; 129 (5) 1056-1063
• 14 Jamieson WR, Riess FC, Raudkivi PJ , et al. Medtronic Mosaic porcine bioprosthesis: assessment of 12-year performance. J Thorac Cardiovasc Surg 2011; 142 (2) 302-307, e2
• 15 Riess FC, Cramer E, Hansen L , et al. Clinical results of the Medtronic Mosaic porcine bioprosthesis up to 13 years. Eur J Cardiothorac Surg 2010; 37 (1) 145-153
• 16 Eichinger WB, Hettich IM, Ruzicka DJ , et al. Twenty-year experience with the St. Jude medical Biocor bioprosthesis in the aortic position. Ann Thorac Surg 2008; 86 (4) 1204-1210
• 17 Mykén PS, Bech-Hansen O. A 20-year experience of 1712 patients with the Biocor porcine bioprosthesis. J Thorac Cardiovasc Surg 2009; 137 (1) 76-81
• 18 Jamieson WR, Burr LH, Miyagishima RT , et al. Carpentier-Edwards supra-annular aortic porcine bioprosthesis: clinical performance over 20 years. J Thorac Cardiovasc Surg 2005; 130 (4) 994-1000
• 19 Minami K, Zittermann A, Schulte-Eistrup S, Koertke H, Körfer R. Mitroflow synergy prostheses for aortic valve replacement: 19 years experience with 1,516 patients. Ann Thorac Surg 2005; 80 (5) 1699-1705
• 20 Kolominsky-Rabas PL, Sarti C, Heuschmann PU , et al. A prospective community-based study of stroke in Germany—the Erlangen Stroke Project (ESPro): incidence and case fatality at 1, 3, and 12 months. Stroke 1998; 29 (12) 2501-2506
• 21 Mykén PS. Seventeen-year experience with the St. Jude medical Biocor porcine bioprosthesis. J Heart Valve Dis 2005; 14 (4) 486-492
• 22 Yankah CA, Pasic M, Musci M , et al. Aortic valve replacement with the Mitroflow pericardial bioprosthesis: durability results up to 21 years. J Thorac Cardiovasc Surg 2008; 136 (3) 688-696
• 23 Khan SS, Trento A, DeRobertis M , et al. Twenty-year comparison of tissue and mechanical valve replacement. J Thorac Cardiovasc Surg 2001; 122 (2) 257-269
• 24 Aupart MR, Mirza A, Meurisse YA, Sirinelli AL, Neville PH. Perimount pericardial bioprosthesis for aortic calcified stenosis: 18-year experience with 1133 patients. J Heart Valve Dis 2006; 15: 768-775
• 25 Borger MA, Ivanov J, Amstron S, Feindel CM, David TE. Twenty-year results of the Hancock II Bioprosthesis. J Heart Valve Dis 2006; 15: 49-55